CCL

Összesen 6 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM111995
Első szerző:Balázs Gergely (csecsemő- és gyermekgyógyász, neonatológus)
Cím:Comparison of flexible nasogastric tube and semi-rigid catheter during less invasive surfactant administration / Gergely Balázs, Ivett Pecsi, Csilla Feher, Nora Katona, Tunde Kotorman, Balazs Kovacs-Paszthy, Mariann Marki, Istvan Pataki, Magdolna Riszter, Timea Rozsa, Gusztav Belteki, Tamas Kovacs, Gyorgy Balla, Andras Balajthy
Dátum:2023
ISSN:2724-5780
Megjegyzések:BACKGROUND: Various flexible and semi-rigid catheter techniques have been reported for surfactant delivery during less invasive surfactant administration (LISA) in preterm infants. Data on the effect of catheter selection on procedural success rates and adverse events are limited. Our objective was to compare the rates of success and adverse events of LISA performed with nasogastric tube and semi-rigid catheter. METHODS: This was a post-hoc analysis of data from a quality improvement project. LISA was performed according to the standardized local protocol. Baseline characteristics, data on performance of LISA, degree of difficulty in laryngoscopy and vital parameters after the initiation of LISA were collected and outcomes were compared between groups. RESULTS: Fifty-six infants were included (21 with nasogastric tube, and 35 with semi-rigid catheter). Procedure success rate (defined as a single LISA attempt resulting in intratracheal administration of the planned dose of surfactant), incidence of adverse events, heart rate and oxygen saturation values and outcomes did not differ significantly between the two groups. When using a nasogastric tube for LISA, a significantly higher fraction of inspired oxygen was needed in the 3rd (0.62 vs. 0.48, P=0.024), 4th (0.61 vs. 0.37, P<0.001) and 5th minute (0.48 vs. 0.37, P=0.001) to maintain normal oxygen saturations. CONCLUSIONS: Use of the semi-rigid catheter was associated with better oxygenation during and shortly after the procedure. Our results may help neonatal units to develop local guidelines.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Minerva Pediatrics. - [Epub ahead of print] (2023). -
További szerzők:Pécsi Ivett Fehér Csilla Katona Nóra Kotormán Tünde Kovács-Pászthy Balázs Márki Mariann (1987-) (csecsemő- és gyermekgyógyász) Pataki István (1975-) (csecsemő és gyermekgyógyász, neonatológus) Riszter Magdolna (1973-) (csecsemő és gyermekgyógyász, neonatológus) Rózsa Tímea (1985-) (csecsemő- és gyermekgyógyász) Bélteki Gusztáv (1970-) (csecsemő és gyermekgyógyász, neonatológus) Kovács Tamás Balla György (1953-) (csecsemő és gyermekgyógyász, neonatológus) Balajthy András (1988-) (általános orvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM066962
Első szerző:Biró Erika
Cím:Acute interstitial nephritis in T-cell leukemia in a pediatric patient / Biro Erika, Szikszay Edit, Pethő-Orosz Petronella, Bigida László, Balla György, Szabó Tamás
Dátum:2016
ISSN:1328-8067
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Pediatrics International. - 58 : 9 (2016), p. 940-942. -
További szerzők:Szikszay Edit Orosz Petronella (1986-) (klinikai orvos) Bigida László Balla György (1953-) (csecsemő és gyermekgyógyász, neonatológus) Szabó Tamás (1968-) (gyermekgyógyász)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM047611
035-os BibID:PMID:20008423
Első szerző:Carbonell-Estrany, Xavier
Cím:Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children : a noninferiority trial / Xavier Carbonell-Estrany, Eric A. F. Simões, Ron Dagan, Caroline B. Hall, Brian Harris, Micki Hultquist, Edward M. Connor, Genevieve A. Losonsky, Motavizumab Study Group
Dátum:2010
Megjegyzések:Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizumab. METHODS: This randomized, double-blind, multinational, phase 3, noninferiority trial assessed safety and RSV hospitalization in 6635 preterm infants aged <or=6 months at enrollment or children aged <or=24 months with chronic lung disease of prematurity who received 15 mg/kg palivizumab or motavizumab monthly. Secondary end points included outpatient medically attended lower respiratory tract infections (MALRIs), RSV-specific LRIs, otitis media, antibiotic use, development of antimotavizumab antibodies, and motavizumab serum concentrations. RESULTS: Motavizumab recipients had a 26% relative reduction in RSV hospitalization compared with palivizumab recipients, achieving noninferiority. Motavizumab was superior to palivizumab for reduction of RSV-specific outpatient MALRIs (50% relative reduction). Overall, adverse events (AEs) were not significantly different between groups. Cutaneous events were reported in 2 percentage points more motavizumab recipients (7.2% vs 5.1%); most were mild, but 0.3% resulted in dosing discontinuation. Antidrug antibodies (ADA) were detected in 1.8% of motavizumab recipients. Patients with anti-drug antibody reported 6 RSV events and 17 cutaneous events. CONCLUSIONS: Children receiving prophylaxis with motavizumab or palivizumab had low rates of RSV hospitalization; motavizumab recipients experienced 50% fewer RSV MALRIs than palivizumab recipients. AEs were similar in both groups, although cutaneous AEs were higher for motavizumab recipients. Motavizumab may offer an improved alternative in prophylaxis for serious RSV disease in infants and children at high risk.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Pediatrics. - 125 : 1 (2010), p. e35-e51. -
További szerzők:Simões, Erik A. F. Dagan, Ron Hall, Caroline B. Harris, Brian Hultquist, Micki Connor, Edward M. Losonsky, Genevieve A. Balla György (1953-) (csecsemő és gyermekgyógyász, neonatológus) Motavizumab Study Group
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

4.

001-es BibID:BIBFORM111435
035-os BibID:(WOS)000814869400008 (Scopus)85127329629
Első szerző:Dani, Carlo
Cím:A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome / Carlo Dani, Gyula Talosi, Annalisa Piccinno, Virginia Maria Ginocchio, Gyorgy Balla, Anna Lavizzari, Zbynek Stranak, Eloisa Gitto, Stefano Martinelli, Richard Plavka, Barbara Krolak-Olejnik, Gianluca Lista, Francesca Spedicato, Giorgia Ciurlia, Debora Santoro, David Sweet, CURONEB Study Group
Dátum:2022
ISSN:0022-3476
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Journal Of Pediatrics. - 246 (2022), p. 40-47.e5. -
További szerzők:Tálosi Gyula Piccinno, Annalisa Ginocchio, Virginia Maria Balla György (1953-) (csecsemő és gyermekgyógyász, neonatológus) Lavizzari, Anna Stranak, Zbynek Gitto, Eloisa Martinelli, Stefano Plavka, Richard Krolak-Olejnik, Barbara Lista, Gianluca Spedicato, Francesca Ciurlia, Giorgia Santoro, Debora Sweet, David CURONEB Study Group
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM070389
Első szerző:Lakatos Lajos
Cím:Metal mediated bilirubin encephalopathy : treatment with D-Penicillamine / Lakatos Lajos, Balla György, Pataki István
Dátum:2017
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Pediatrics & Neonatal Biology. - 1 : 2 (2017), p. 1-4. -
További szerzők:Balla György (1953-) (csecsemő és gyermekgyógyász, neonatológus) Pataki István (1975-) (csecsemő és gyermekgyógyász, neonatológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM025024
Első szerző:Laughon, Matthew
Cím:A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia / Laughon, M., Bose, C., Moya, F., Aschner, J., Donn, S. M., Morabito, C., Cummings, J. J., Segal, R., Guardia, C., Liu, G., Surfaxin Study Group
Dátum:2009
ISSN:0031-4005
Megjegyzések:Oxidant injury and lung inflammation in extremely premature infants are associated with the development of bronchopulmonary dysplasia. Surfactant dysfunction resulting from these events may contribute to the pathogenesis of bronchopulmonary dysplasia. Treatment with exogenous surfactant may decrease the incidence or severity of bronchopulmonary dysplasia. We conducted a masked, multicenter, multinational, randomized, controlled, pilot study to estimate the effects of treating infants at high risk for developing bronchopulmonary dysplasia with lucinactant, a synthetic, peptide-containing surfactant, on safety during dosing and the incidence of death or bronchopulmonary dysplasia. METHODS: Preterm infants between 600 and 900 g requiring mechanical ventilation and a fraction of inspired oxygen of > or =0.30 between 3 and 10 days of age were randomly assigned to receive either sham air (placebo) or 1 of 2 doses of lucinactant (90 or 175 mg/kg total phospholipid) every 48 hours to a maximum of 5 doses, if they remained on mechanical ventilation. RESULTS: Of 136 infants enrolled at 34 sites, 44 received placebo, 47 received 90 mg/kg total phospholipid, and 45 received 175 mg/kg total phospholipid. The 90 mg/kg group had a significantly higher percentage of boys (64%) compared with the placebo group (39%); no other significant differences in baseline characteristics among groups were present. Compared with placebo, both the 90 mg/kg and 175 mg/kg groups experienced a significantly higher incidence of desaturation and bradycardia during dosing. Twenty-four hours after dosing, the mean fraction of inspired oxygen was lower in both lucinactant groups (33%) compared with the placebo group (39%). The incidence of mortality or bronchopulmonary dysplasia was 66% in the placebo group, 79% in the 90 mg/kg group, and 58% in the 175 mg/kg group. These differences were not statistically significant. There were no statistical differences among groups for pneumothorax, pulmonary interstitial emphysema, intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, or mortality. CONCLUSIONS: There were trends toward lower oxygen requirements and toward a lower incidence of mortality or bronchopulmonary dysplasia at 36 weeks' postmenstrual age in infants who received the higher dose of lucinactant, and this warrants further investigation.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
premature infant
surfactant
bronchopulmonary dysplasia
Megjelenés:Pediatrics 123 : 1 (2009), p. 89-96. -
További szerzők:Bose, Carl Moya, Fernando Aschner, Judy Donn, Steven Mark Morabito, Christopher Cummings, James John Segal, Robert Guardia, Carlos Liu, Genzhou Balla György (1953-) (csecsemő és gyermekgyógyász, neonatológus) Polonkai Edit (1965-) (csecsemő és gyermekgyógyász, neonatológus) Surfaxin Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.